Journal of Cancer Therapy
Vol.8 No.8(2017), Paper ID 78044, 8
pages
DOI:10.4236/jct.2017.88059
Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma
Alina S. Fedorova, Maria V. Stegantseva, Nina V. Minakovskaya, Olga V. Aleinikova
Clinical Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
Laboratory of Genetic Biotechnology, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
Department of Bone Marrow Transplantation, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
Clinical Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
Copyright © 2017 Alina S. Fedorova, Maria V. Stegantseva, Nina V. Minakovskaya, Olga V. Aleinikova et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Fedorova, A. , Stegantseva, M. , Minakovskaya, N. and Aleinikova, O. (2017) Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma.
Journal of Cancer Therapy,
8, 683-690. doi:
10.4236/jct.2017.88059.